BELLUS Health Inc (BLU) – Strategy, SWOT and Corporate Finance Report

BELLUS Health Inc (BLU) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

BELLUS Health Inc (BELLUS Health) is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small-molecule antagonist of the P2X3 receptor which is being developed for treating refractory chronic cough, and chronic pruritus associated with atopic dermatitis. The company has license agreement and collaborations with NEOMED institute for the development and commercialization of BLU-593. The company operates in Canada and the US through its subsidiaries. BELLUS Health is headquartered in Laval, Quebec, Canada.

Scope

• Detailed information on BELLUS Health Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting BELLUS Health Inc in the form of a SWOT analysis

• An in-depth view of the business model of BELLUS Health Inc including a breakdown and examination of key business segments

• News about BELLUS Health Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of BELLUS Health Inc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess BELLUS Health Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on BELLUS Health Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

VYNE Therapeutics Inc

Shionogi Inc

Merck Canada Inc

Cara Therapeutics Inc

Pfizer Inc

Vanda Pharmaceuticals Inc

Novartis Pharmaceuticals Canada Inc

Genzyme Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

BELLUS Health Inc - Key Facts

BELLUS Health Inc - Key Employees

BELLUS Health Inc - Key Employee Biographies

BELLUS Health Inc - Major Products and Services

BELLUS Health Inc - History

BELLUS Health Inc - Company Statement

BELLUS Health Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

BELLUS Health Inc - Business Description

BELLUS Health Inc - Corporate Strategy

BELLUS Health Inc - SWOT Analysis

SWOT Analysis - Overview

BELLUS Health Inc - Strengths

BELLUS Health Inc - Weaknesses

BELLUS Health Inc - Opportunities

BELLUS Health Inc - Threats

BELLUS Health Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

BELLUS Health Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Apr 19, 2023: GSK to acquire BELLUS Health for $2bn

Nov 14, 2022: BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 10, 2022: BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

Sep 06, 2022: BELLUS Health presentation at the HC Wainwright Global Investment Conference

Aug 10, 2022: BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

Jun 01, 2022: BELLUS Health will participate in the Jefferies Healthcare Conference

May 11, 2022: BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

Feb 23, 2022: BELLUS Health Reports Year 2021 Financial Results and Business Highlights

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

BELLUS Health Inc, Key Facts

BELLUS Health Inc, Key Employees

BELLUS Health Inc, Key Employee Biographies

BELLUS Health Inc, Major Products and Services

BELLUS Health Inc, History

BELLUS Health Inc, Subsidiaries

BELLUS Health Inc, Key Competitors

BELLUS Health Inc, Ratios based on current share price

BELLUS Health Inc, Annual Ratios

BELLUS Health Inc, Annual Ratios (Cont…1)

BELLUS Health Inc, Interim Ratios

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

BELLUS Health Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

BELLUS Health Inc, Performance Chart (2018 – 2022)

BELLUS Health Inc, Ratio Charts

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports